Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Conditions

Diseases of the Nervous System | Alzheimer's Disease

Phase III

What is the purpose of this trial?

Brief Summary:

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

  • Trial with
    Genentech, Inc.
  • Start Date
    01/03/2019
  • End Date
    05/30/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Hugh Bartlett

  • Last Updated
    07/23/2019
  • Study HIC
    #2000021691